DALLAS, TX -- (Marketwired) -- 12/02/13 -- Cerebain Biotech Corp. ("Cerebain" or "the Company"), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today that it has engaged Superior Inc. to represent the Company in Poland for the purpose of Clinical Testing of the Company's Medical Device for the treatment of Alzheimer's Disease utilizing the Omentum. The Consulting firm will serve as the intermediary in Poland to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing once the Company's prototype is completed. The medical device is being developed by Cerebain Biotech Corp as a potential new approach for the treatment for patients suffering from Alzheimer's and Dementia.
Eric Clemons, President, Cerebain Biotech Corp., said: "We are excited to have Mr. Salnik and his team representing us in Poland. They bring a wealth of local knowledge and relationships developed over time. Once our prototype is completed, we will begin to evaluate the device's efficacy and safety in human subjects. If successful, such trials may lead to the development of a new approach to the treatment of Alzheimer's Disease."
About Discount Dental Materials, Inc.
Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company's business involves the discovery of products for the treatment of Alzheimer's disease utilizing Omentum. The Company's planned products include both a medical device solution as well as a synthetic drug solution. The Company's operations are conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company's website at www.cerebain.com and www.otcmarkets.com, under the ticker symbol "DDOO," to view the Company's public filings and stock quote.
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.